Tarsus Pharmaceuticals (NASDAQ: $TARS) has begun dosing in Calliope, a 700‑subject Phase 2 trial of TP‑05 for Lyme Disease prevention. Earlier “tick‑kill” data were strong; now the focus shifts to broader safety/PK in at‑risk adults.
#TarsusPharma #LymeDisease
prismmarketview.com/tarsus-kicks...